Clinical trial regulations in 2026: what to look out for and how to prepare
Why regulatory change feels constant in clinical research
For many people working in clinical research, regulatory change doesn’t feel like something that happens every few years anymore. It feels continuous.
This isn’t because regulators are changing their minds all the time. It’s because the way trials are run has changed. Studies are more global. Teams are more distributed. Data is generated and transferred across multiple systems, vendors, and countries. At the same time, there is growing pressure to run trials faster while maintaining quality and patient safety.
Regulators are responding to this reality. Instead of prescribing very detailed “how-to” rules, they are focusing more on principles, risk awareness, and decision-making.
That’s why clinical trial regulation today is less about memorising requirements and more about understanding intent. And that shift will be even more visible as we move into 2026.
Regulatory updates to watch in 2026
As we move toward 2026, it’s becoming clearer that regulatory updates are less about introducing brand-new rules and more about refining how existing frameworks are applied.
Standards and guidelines that teams may already be familiar with are being looked at through a more practical lens, with greater attention to how decisions are made in real study conditions.
Understanding where expectations are shifting helps teams prepare before those questions come up during audits or inspections.
An updated edition of ISO 14155 for better regulatory alignment
ISO 14155 has been around for a while, but it continues to evolve. We are expecting an updated version in the coming period, with industry signals pointing to 2026. The main focus will be on creating alignment between all global regulatory changes in clinical research, and especially the EU Medical Device Regulations.
What we are expecting from it:
– Spotlight on integrating risk management throughout the entire clinical research process
– Additional clarification on data management and clinical investigation audits
– Clearer ethical expectations around patient consent, and more precise definitions of clinical performance for medical devices
However, details are yet to be confirmed, so stay tuned.
Nonetheless, one thing is sure: ISO 14155 requirements will impact internal procedures for many clinical research teams and adaptability will be vital for success.
For teams working on medical device trials, ISO 14155 is closely tied to clinical trial compliance. Understanding how the standard connects to real study conduct is becoming just as important as knowing its clauses.
Annex II of ICH-GCP E6 (R3): applying judgement, not just procedures
ICH-GCP E6 (R3) is often described as a “new version” of GCP, but in reality, it’s more of a shift in mindset. Annex 1 has been published and is beginning to be implemented, with Annex 2 expected in 2026 as a key component of ICH-GCP E6 (R3), including its application to non-traditional and innovative clinical trial designs.
What the ICH-GCP E6 (R3) focuses on:
– Planning for quality early through proactive risk management (not just paperwork after the fact).
– Ensuring robust data integrity and oversight, particularly for electronic systems and digital tools.
– Supporting modern trial methods (eConsent, wearables, remote monitoring, real-world evidence), while clarifying responsibilities across sponsors, investigators, and vendors.
– Clearer principles on making clinical trials proportionate, safe for participants, and reliable in data quality.
The ICH-GCP E6 (R3) introduces important foundational changes for clinical research. While the principles may appear straightforward on paper, applying them consistently in practice can be far more challenging.
It reflects a broader shift in regulation, moving away from adding more checklists toward building a mindset focused on proactive planning, innovation, and thoughtful decision-making.
This transition should not be underestimated, and teams will benefit from building confidence in ICH-GCP E6 (R3) early on.
Skills becoming more important as regulations evolve
Regulatory changes don’t just affect SOPs. They affect the skills people need in their day-to-day roles.
As expectations shift toward risk-based thinking, data awareness, and sound judgement, teams are being asked to move beyond following procedures and toward understanding the reasoning behind them. Building these skills early makes it easier to adapt as regulations continue to evolve.
Data management and data security awareness
As trials become more digital, data integrity is no longer limited to a single system or department.
Clinical teams are expected to have a basic understanding of:
- where data originates (ePRO, labs, imaging, vendors)
- how it moves between systems
- where potential risks to data quality or security may arise
This doesn’t mean everyone needs to be a data expert. But regulators increasingly expect teams to understand the data landscape well enough to spot issues and ask the right questions.
In that sense, data awareness has become a core part of compliance in clinical trials, not a niche topic.
Risk-Based Quality Management as an ongoing process
Risk-based quality management is now central to many EU clinical trial regulation updates, but it’s still often misunderstood.
It’s not about creating a single risk assessment at the start of the study and filing it away. It’s about regularly revisiting risks such as:
- Study progresses
- New sites added
- Vendor changes
- Unexpected issues occur
In 2026, regulators will expect risk management to be visible throughout the study lifecycle. Teams that treat risk as a living topic (discussed, reviewed, and adjusted) are much better positioned during audits.
The importance of refreshing your knowledge regularly
Many compliance gaps don’t come from new regulations. They come from outdated interpretations of existing ones.
Some regulations are being updated, others are interpreted differently over time, and many now need to be applied alongside new guidance.
Frameworks like EU CTR 536/2014 and GCP continue to evolve in practice, especially as they intersect with newer expectations around risk, data integrity, and oversight. Without regular updates, teams can quickly fall behind the pace of change or apply regulations in ways that no longer align with current expectations.
Refreshing knowledge helps teams:
- Realigning around current expectations
- Challenging assumptions that no longer hold
- Applying regulations more consistently across studies
Refreshing your knowledge is not just about keeping up with new regulations but understanding how they intersect with old ones and navigating these changes throughout the entire clinical process.
What this means for clinical teams in practice
Preparing for upcoming clinical trial regulations doesn’t mean trying to predict every future update. It means strengthening how teams think and work today.
Practical steps many organisations are taking include:
- Reviewing how regulatory principles are applied in daily decisions
- Focusing training on real scenarios rather than theoretical rules
- Encouraging teams to document reasoning, not just outcomes
- Planning regular updates instead of one-off training sessions
Many teams also rely on external regulatory training to stay aligned with inspection trends and industry-wide expectations, especially when internal resources are stretched.
Final thoughts
Clinical trial regulation in 2026 will continue to move toward principles, judgement, and accountability.
Teams that feel confident explaining why they made a decision (not just what they did) will be better prepared for inspections, audits, and daily challenges.
Staying informed, refreshing knowledge, and building practical skills won’t eliminate regulatory pressure. But it will make navigating it far more manageable.